Journal article
Building better monoclonal antibody-based therapeutics
Nature reviews. Cancer, Vol.15(6), pp.361-370
06/2015
DOI: 10.1038/nrc3930
PMCID: PMC4491443
PMID: 25998715
Abstract
For 20 years, monoclonal antibodies (mAbs) have been a standard component of cancer therapy, but there is still much room for improvement. Efforts continue to build better cancer therapeutics based on mAbs. Anticancer mAbs function through various mechanisms, including directly targeting the malignant cells, modifying the host response, delivering cytotoxic moieties and retargeting cellular immunity towards the malignant cells. Characteristics of mAbs that affect their efficacy include antigen specificity, overall structure, affinity for the target antigen and how a mAb component is incorporated into a construct that can trigger target cell death. This Review discusses the various approaches to using mAb-based therapeutics to treat cancer and the strategies used to take advantage of the unique potential of each approach, and provides examples of current mAb-based treatments.
Details
- Title: Subtitle
- Building better monoclonal antibody-based therapeutics
- Creators
- George J Weiner - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Nature reviews. Cancer, Vol.15(6), pp.361-370
- DOI
- 10.1038/nrc3930
- PMID
- 25998715
- PMCID
- PMC4491443
- NLM abbreviation
- Nat Rev Cancer
- ISSN
- 1474-175X
- eISSN
- 1474-1768
- Grant note
- P30 CA86862 / NCI NIH HHS P50 CA97274 / NCI NIH HHS P30 CA086862 / NCI NIH HHS P50 CA097274 / NCI NIH HHS
- Language
- English
- Date published
- 06/2015
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Pharmaceutical Sciences and Experimental Therapeutics; Internal Medicine
- Record Identifier
- 9984359561202771
Metrics
28 Record Views